EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma. Sadeghi S, Quinn D, Dorff T, Pal S, et al. J Clin Oncol 2023;41:640-650.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sadeghi S, Quinn D, Dorff T, Pal S, et al. EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma. J Clin Oncol 2023;41:640-650.
PMID: 35984996